NCT02237157View on ClinicalTrials.gov

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine, local delivery

Intra-arterial targeted drug delivery

Trial Locations (2)

33613

Florida Hospital, Tampa

94040

El Camino Hospital, Oncology, Mountain View

Sponsors

Lead Sponsor

RenovoRx
All Listed Sponsors
lead

RenovoRx

INDUSTRY